Graft-Versus-Host Disease
DOR BioPharma Announces Potential $30 Million North American Partnership Agreement with Sigma-Tau Pharmaceuticals for orBec(R) in the Treatment of Graft-versus-Host Disease
Published in Medical Letter on the CDC and FDA, March 1st, 2009
As part of the agreement, Sigma-Tau will make a $6 million upfront investment in DOR, inclusive of the $1.5 million which was recently completed under a letter of intent dated November 26, 2008. The remaining $4.5 million investment was priced at a 50% premium to the five day trailing average of DOR stock, putting the investment price at $0.18 per share. In...
Want to see the full article?
We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Medical Letter on the CDC and FDA
More Articles from Medical Letter on the CDC and FDA
- JAMA and Archives Journals
Immunosuppressant medication may be cost-effective for dry eye syndrome - Research
Molecules help the immune system to detect cells infected with West Nile virus - Breast Implants
Research from Georgetown University in the area of breast implants published - Cancer
FDA approves clinical studies of a novel anti-cancer drug developed by the Italian research; Nerviano Medical Sciences (NMS)gets green light from the FDA - Natural Products Association
Evidence Lacking in Multivitamin Study of Women's Risk of Cancer, Heart Disease or Death, Says Natural Products Association - OSI Pharmaceuticals, Inc.
OSI Pharmaceuticals Announces Notification of ANDA Filing for Tarceva - More from this issue of Medical Letter on the CDC and FDA
NewsRx is Social
Follow us on your favorite social network by clicking on a button below:
Top Medical Newsletters
Awards
Best Health/Healthcare Content, 2012
Best Health/Healthcare Content, 2011
Best e-Business Site, 2010
Best e-Business Site, 2009
Best e-Business Site, 2008
Best e-Business Site, 2007
Best e-Business Site, 2006
Best Healthcare Content, 2005
Best Overall Internet Site, 2005
Best Interactive Site, 2005
Facts & Stats
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.
- Google 2010 PageRank: #2 Among Top Health News and Media Publications
- Google 2010 PageRank: #2 Among Top Science Publications in Biology/Physiology
- Google 2010 PageRank: #2 Among Top News and Media for the Business of Pharmaceuticals
- Amazon's Alexa 2010 PageRank: #2 News and Media Site for the Pharmaceutical Industry
